NIKKEI 225
37,552.16 +113.55 (+0.30%) HANG SENG
16,828.93 +317.24 (+1.92%) CRUDE OIL
83.30 +1.40 (+1.71%) GOLD FUTURES
2,341.60 -4.80 (-0.20%) DOW
38,499.49 +259.51 (+0.68%) Bitcoin GBP
53,574.04 +68.70 (+0.13%)
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SFOSF)
| Previous close | 1.5320 |
| Open | 1.5200 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 1.5320 - 1.5320 |
| 52-week range | 1.5150 - 2.9150 |
| Volume | |
| Avg. volume | 7,141 |
| Market cap | 7.492B |
| Beta (5Y monthly) | 0.67 |
| PE ratio (TTM) | 11.78 |
| EPS (TTM) | 0.1300 |
| Earnings date | N/A |
| Forward dividend & yield | 0.06 (3.83%) |
| Ex-dividend date | 31 Jul 2023 |
| 1y target est | N/A |
- PR Newswire
Fosun Pharma's Global Multi-Center Phase III Clinical Trial Project for A New Antimalarial Drug Receives 500 Million Japanese Yen Investment from GHIT Fund to Jointly Improve the Global Accessibility of Antimalarial Drugs
The Japan-based Global Health Innovative Technology Fund (GHIT Fund) announced today that it will invest approximately US$3.3 million (approximately 500 million yen[1]) in a global multicenter Phase III clinical trial project (the "Program") led by Fosun Pharma for a triple artemisinin combination drug (Artemether-Lumefantrine-Amodiaquine fixed-dose formulation) against malaria in Africa and Southeast Asia, to accelerate the development and commercialization of this new drug.
- Investing.com
Cevira Phase III trial for non-surgical HSIL treatment meets primary endpoint
Photocure ASA (OSE: PHO) and its partner Asieris Pharmaceuticals (SSE (LON:SSE): 688176) announced on Wednesday that their multinational Phase III clinical trial for Cevira (APL-1702) has successfully met its primary endpoint. Cevira, a photodynamic drug-device combination product, is in development for the non-surgical treatment of high-grade squamous intraepithelial lesions (HSIL).
